S'abonner

Atopic eczema and major cardiovascular outcomes: A systematic review and meta-analysis of population-based studies - 04/05/19

Doi : 10.1016/j.jaci.2018.11.030 
Anna Ascott, MBBS, MSc a, , Amy Mulick, MSc b, , Ashley M. Yu, MD c, David Prieto-Merino, PhD b, Morten Schmidt, PhD d, Katrina Abuabara, MD, MA, MSCE e, Liam Smeeth, PhD b, Amanda Roberts, BSc f, Sinéad M. Langan, FRCP, PhD b
a Royal Sussex County Hospital, Eastern Road, Brighton, United Kingdom 
b Department of Non-Communicable Disease Epidemiology, London School of Hygiene and Tropical Medicine, London, United Kingdom 
c Faculty of Medicine, University of Ottawa, Ottawa, Ontario, Canada 
d Department of Clinical Epidemiology, Aarhus University Hospital, Denmark Department of Cardiology, Regional Hospital West Jutland, Herning, Denmark 
e Program for Clinical Research, Department of Dermatology, University of California, San Francisco School of Medicine, San Francisco, Calif 
f Nottingham Support Group for Carers of Children with Eczema, Nottingham, United Kingdom 

Corresponding author: Anna Ascott, MBBS, MSc, Royal Sussex County Hospital, Eastern Road, Brighton BN2 5BE, United Kingdom.Royal Sussex County HospitalEastern RoadBrightonBN2 5BEUnited Kingdom

Abstract

Background

Atopic eczema is a common inflammatory skin disease. Various inflammatory conditions have been linked to cardiovascular disease, a major cause of global mortality and morbidity.

Objective

We sought to systematically review and meta-analyze population-based studies assessing associations between atopic eczema and specific cardiovascular outcomes.

Methods

MEDLINE, Embase, and Global Health were searched from inception to December 2017. We obtained pooled estimates using random-effects meta-analyses. We used a multivariate Bayesian meta-regression model to estimate the slope of effect of increasing atopic eczema severity on cardiovascular outcomes.

Results

Nineteen relevant studies were included. The effects of atopic eczema reported in cross-sectional studies were heterogeneous, with no evidence for pooled associations with angina, myocardial infarction, heart failure, or stroke. In cohort studies atopic eczema was associated with increased risk of myocardial infarction (n = 4; relative risk [RR], 1.12; 95% CI, 1.00-1.25), stroke (n = 4; RR, 1.10; 95% CI, 1.03-1.17), ischemic stroke n = 4; RR, 1.17; 95% CI, 1.14-1.20), angina (n = 2; RR, 1.18; 95% CI, 1.13-1.24), and heart failure (n = 2; RR, 1.26; 95% CI, 1.05-1.51). Prediction intervals were wide for myocardial infarction and stroke.

The risk of cardiovascular outcomes appeared to increase with increasing severity (mean RR increase between severity categories, 1.15; 95% credibility interval, 1.09-1.21; uncertainty interval, 1.04-1.28).

Conclusion

Significant associations with cardiovascular outcomes were more common in cohort studies but with considerable between-study heterogeneity. Increasing atopic eczema severity was associated with increased risk of cardiovascular outcomes. Improved awareness among stakeholders regarding this small but significant association is warranted.

Le texte complet de cet article est disponible en PDF.

Key words : Atopic eczema, atopic dermatitis, angina, myocardial infarction, heart failure, stroke, ischemic stroke, cardiovascular death, cardiovascular outcomes, risk factors

Abbreviations used : CrI, CVD, GRADE, HR, IRR, OR, PI, PRISMA, PROSPERO, RR


Plan


 PROSPERO registration no. CRD42017060359.
 A.A. reports grants from the British Association of Dermatologists during the conduct of the study. K.A. reports grants from the National Institutes of Health, Robert Wood Johnson Foundation, and Dermatology Foundation during the conduct of the study. L.S. reports grants from the Wellcome Trust. S.M.L. reports grants from Wellcome Senior Clinical Fellowship in Science (205039/Z/16/Z) during the conduct of the study (A.M. is also funded on this fellowship). The Wellcome Trust and the British Association of Dermatologists played no role in the development or results of this study, and all authors carried out this research independently of the funding bodies. The findings and conclusions in this report are those of the authors and do not necessarily represent the views of the funders.
 Disclosure of potential conflict of interest: A. Ascott reports grants from the British Association of Dermatologists during the conduct of the study. K. Abuabara reports grants from the National Institutes of Health, Robert Wood Johnson Foundation, and Dermatology Foundation during the conduct of the study. L. Smeeth reports grants from the Wellcome Trust during the conduct of the study; reports grants from the Wellcome Trust, Medical Research Council, National Institute for Health Research, and European Union outside the submitted work; reports personal fees from GlaxoSmithKline for advisory work unrelated to the submitted work; reports grant funding from GlaxoSmithKline for academic research unrelated to the submitted work; acts as an unpaid steering committee chair for AstraZeneca for a randomized trial unrelated to the submitted work; and is a trustee of the British Heart Foundation. S. M. Langan reports grants from Wellcome Senior Clinical fellowship in Science (205039/Z/16/Z) during the conduct of the study (A. Mulick is also funded on this fellowship). The rest of the authors declare that they have no relevant conflicts of interest.


© 2018  The Authors. Publié par Elsevier Masson SAS. Tous droits réservés.
Ajouter à ma bibliothèque Retirer de ma bibliothèque Imprimer
Export

    Export citations

  • Fichier

  • Contenu

Vol 143 - N° 5

P. 1821-1829 - mai 2019 Retour au numéro
Article précédent Article précédent
  • Identification and prospective stability of electronic nose (eNose)–derived inflammatory phenotypes in patients with severe asthma
  • Paul Brinkman, Ariane H. Wagener, Pieter-Paul Hekking, Aruna T. Bansal, Anke-Hilse Maitland-van der Zee, Yuanyue Wang, Hans Weda, Hugo H. Knobel, Teunis J. Vink, Nicholas J. Rattray, Arnaldo D'Amico, Giorgio Pennazza, Marco Santonico, Diane Lefaudeux, Bertrand De Meulder, Charles Auffray, Per S. Bakke, Massimo Caruso, Pascal Chanez, Kian F. Chung, Julie Corfield, Sven-Erik Dahlén, Ratko Djukanovic, Thomas Geiser, Ildiko Horvath, Nobert Krug, Jacek Musial, Kai Sun, John H. Riley, Dominic E. Shaw, Thomas Sandström, Ana R. Sousa, Paolo Montuschi, Stephen J. Fowler, Peter J. Sterk, U-BIOPRED Study Group ?
| Article suivant Article suivant
  • Efficacy and safety of the histamine H4 receptor antagonist ZPL-3893787 in patients with atopic dermatitis
  • Thomas Werfel, Gary Layton, Michael Yeadon, Lyndsey Whitlock, Ian Osterloh, Pablo Jimenez, Wai Liu, Victoria Lynch, Aliya Asher, Athanasios Tsianakas, Lynn Purkins

Bienvenue sur EM-consulte, la référence des professionnels de santé.
L’accès au texte intégral de cet article nécessite un abonnement.

Déjà abonné à cette revue ?

Mon compte


Plateformes Elsevier Masson

Déclaration CNIL

EM-CONSULTE.COM est déclaré à la CNIL, déclaration n° 1286925.

En application de la loi nº78-17 du 6 janvier 1978 relative à l'informatique, aux fichiers et aux libertés, vous disposez des droits d'opposition (art.26 de la loi), d'accès (art.34 à 38 de la loi), et de rectification (art.36 de la loi) des données vous concernant. Ainsi, vous pouvez exiger que soient rectifiées, complétées, clarifiées, mises à jour ou effacées les informations vous concernant qui sont inexactes, incomplètes, équivoques, périmées ou dont la collecte ou l'utilisation ou la conservation est interdite.
Les informations personnelles concernant les visiteurs de notre site, y compris leur identité, sont confidentielles.
Le responsable du site s'engage sur l'honneur à respecter les conditions légales de confidentialité applicables en France et à ne pas divulguer ces informations à des tiers.


Tout le contenu de ce site: Copyright © 2024 Elsevier, ses concédants de licence et ses contributeurs. Tout les droits sont réservés, y compris ceux relatifs à l'exploration de textes et de données, a la formation en IA et aux technologies similaires. Pour tout contenu en libre accès, les conditions de licence Creative Commons s'appliquent.